Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2013 - 2019)

Ultragenyx Pharmaceutical (RARE) has 7 years of Change in Account Payables data on file, last reported at $3.9 million in Q3 2019.

• On a quarterly basis, Change in Account Payables rose 298.58% year-over-year to $3.9 million in Q3 2019; TTM through Sep 2019 was $4.2 million, a 517.67% increase from a year earlier, with the FY2018 full-year figure at $3.4 million, down 2.52% from the prior year.
• Change in Account Payables for Q3 2019 stood at $3.9 million, up from -$3.5 million in the prior quarter.
• Over the last five years, Change in Account Payables for RARE reached as high as $4.3 million in Q2 2015 and fell as low as -$5.3 million in Q3 2015.
• Historically, Change in Account Payables has averaged $400894.7 across 5 years, with a median of $187000.0 in 2016.
• On a YoY basis, Change in Account Payables climbed as much as 4528.57% in 2015 and fell as far as 825.92% in 2015.
• Year by year, Change in Account Payables stood at -$1.4 million in 2015, then rose by 6.82% to -$1.3 million in 2016, then soared by 68.66% to -$420000.0 in 2017, then soared by 1044.05% to $4.0 million in 2018, then dropped by 1.39% to $3.9 million in 2019.
• Per Business Quant data, the three most recent Change in Account Payables figures were $3.9 million in Q3 2019, -$3.5 million in Q2 2019, and -$151000.0 in Q1 2019.